Axsome Therapeutics has gained FDA approval for Auvelity to treat agitation linked to Alzheimer’s disease dementia, its second U.S. indication after major depressive disorder. The oral therapy, targeting NMDA and sigma-1 receptors, delivered statistically significant gains in agitation scores during the five-week Advance-1 trial. That result, supported by four studies with over 1,000 participants, sets the drug against Lundbeck and Otsuka’s Rexulti, approved for the same indication in 2023. Yet there’s a critical distinction: Auvelity isn’t an antipsychotic and carries no black box warning for mortality risk in dementia-related psychosis. Investors noticed. Axsome’s shares climbed 12% post-approval, pushing its valuation beyond $10 billion, more than twice where it stood at the start of 2025.
The green light gives Axsome a tangible foothold in one of Alzheimer’s most neglected behavioral domains. Roughly three-quarters of patients experience agitation, and the absence of safe pharmacologic tools has forced physicians to lean on off-label antipsychotics despite well-documented risks. With its non-antipsychotic profile and distinct receptor action, Auvelity introduces a realistic alternative, if payers decide to meet it on even terms with Rexulti. That’s not guaranteed. Insurers and Medicare Part D plans will examine its rapid clinical response, tolerability, and price before locking in access. For those following how formulary teams are weighing new CNS entrants, RxInfo.ai provides recent pricing benchmarks worth a look.
If early prescription trends mirror the company’s depression rollout, Axsome could evolve from a focused psychiatry outfit into a credible neurology contender by 2026. Post-market surveillance will decide how strong that thesis really is. Longer-term durability data from the Accord-2 extension will matter, as real-world patterns often tell a different story than trial snapshots. One possibility: Axsome uses this regulatory momentum to expand into adjacent neuropsychiatric conditions built on the same receptor framework. The firm seems intent on making Auvelity more than a one-indication success. Whether payers stay comfortable with its pricing assumptions is another issue entirely. I wouldn’t bet against more debate before the year is out. Then again, in CNS drug launches, nothing ever moves in a straight line.
